MDT

97.71

-2.09%↓

148.59

+1.08%↑

VEEV

241.39

-0.83%↓

HQY

95.25

-2.39%↓

PHR.US

17.19

+1.9%↑

MDT

97.71

-2.09%↓

148.59

+1.08%↑

VEEV

241.39

-0.83%↓

HQY

95.25

-2.39%↓

PHR.US

17.19

+1.9%↑

MDT

97.71

-2.09%↓

148.59

+1.08%↑

VEEV

241.39

-0.83%↓

HQY

95.25

-2.39%↓

PHR.US

17.19

+1.9%↑

MDT

97.71

-2.09%↓

148.59

+1.08%↑

VEEV

241.39

-0.83%↓

HQY

95.25

-2.39%↓

PHR.US

17.19

+1.9%↑

MDT

97.71

-2.09%↓

148.59

+1.08%↑

VEEV

241.39

-0.83%↓

HQY

95.25

-2.39%↓

PHR.US

17.19

+1.9%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Avatud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

50%

190 / 372 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. jaan 2026, 23:08 UTC

Omandamised, ülevõtmised, äriostud

Rio Tinto, Glencore in Talks to Form World's Biggest Miner -- 3rd Update

8. jaan 2026, 21:39 UTC

Omandamised, ülevõtmised, äriostud

Glencore, Rio Tinto Restart Merger Talks -- 2nd Update

8. jaan 2026, 20:54 UTC

Omandamised, ülevõtmised, äriostud

Glencore, Rio Tinto Restart Merger Talks -- Update

8. jaan 2026, 20:44 UTC

Omandamised, ülevõtmised, äriostud

Glencore, Rio Tinto Restart Merger Talks

8. jaan 2026, 17:05 UTC

Omandamised, ülevõtmised, äriostud

Chinese Anta Sports Products Offers to Buy Pinault Family's Stake in Puma, Reuters Says, Citing Unnamed Sources

8. jaan 2026, 16:43 UTC

Suurimad hinnamuutused turgudel

Babcock & Wilcox Shares Rise on Siemens Deal for Data Center Project

8. jaan 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

8. jaan 2026, 23:37 UTC

Market Talk

Gold Steady, Underpinned by Geopolitical Risks -- Market Talk

8. jaan 2026, 22:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. jaan 2026, 22:42 UTC

Market Talk

RBA Still Battling a Troubling Inflation Outlook, Says TD -- Market Talk

8. jaan 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Glencore, Rio Tinto Confirm Early Merger Talks -- Barrons.com

8. jaan 2026, 21:53 UTC

Tulu

These Stocks Moved the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. jaan 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8. jaan 2026, 21:10 UTC

Omandamised, ülevõtmised, äriostud

Rio Tinto Says Current Expectation That Any Deal Would Involve Buying Glencore Via Scheme of Arrangement

8. jaan 2026, 21:09 UTC

Market Talk

Oil Rises As Trump Said to Back Russia Sanctions Bill -- Market Talk

8. jaan 2026, 21:09 UTC

Omandamised, ülevõtmised, äriostud

Rio Tinto Confirms in Talks With Glencore Over Possible Merger

8. jaan 2026, 20:21 UTC

Market Talk

U.S. Natural Gas Futures Down Despite Inventory Draw -- Market Talk

8. jaan 2026, 19:44 UTC

Market Talk

Gold's Shine Masks Deep Drops in Canada Steel, Aluminum Exports -- Market Talk

8. jaan 2026, 18:50 UTC

Market Talk

Mexico's Industrial Production Seen Lower in November -- Market Talk

8. jaan 2026, 17:48 UTC

Tulu

These Stocks Are Moving the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8. jaan 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. jaan 2026, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8. jaan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

8. jaan 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. jaan 2026, 16:45 UTC

Market Talk

Goldman Lifts 1H LME Copper Forecast -- Market Talk

8. jaan 2026, 16:03 UTC

Market Talk

Global Equities Roundup: Market Talk

8. jaan 2026, 16:03 UTC

Market Talk

Currency Markets Could Be Underpricing Medium-Term Risks -- Market Talk

8. jaan 2026, 16:02 UTC

Market Talk

U.S. Natural Gas Inventories Fall As Expected -- Market Talk

8. jaan 2026, 15:23 UTC

Omandamised, ülevõtmised, äriostud

Paramount Defends Its Hostile Bid for Warner -- Update

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

190 / 372 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.